In December 2021, we entered into a multi-year, strategic collaboration with Roche and Genentech in key areas of neuroscience and an oncology indication. Through the partnership, we are working with both Roche and Genentech's R&D units to leverage our Recursion OS and Maps of Biology, along with extensive single-cell perturbation screening data from Roche and Genentech, to rapidly identify novel biological relationships to initiate and advance therapeutic programs. Together we may initiate up to 40 programs over a decade or longer.

In November 2023, we announced an updated collaboration with our established partner, Bayer, for a select set of precision oncology programs. The collaboration will leverage our state-of-the-art capabilities to initiate and advance the identification of novel therapeutic targets for challenging oncology indications with high unmet need. Under the terms of the agreement, we may initiate up to seven oncology programs and Recursion is eligible to receive potential, success-based, future payments of up to $1.5 billion plus royalties on net sales.

In September 2023, we entered into a collaboration with Merck KGaA, Darmstadt, Germany. This multi-year collaboration utilizes our AI-driven precision drug design and discovery capabilities while leveraging Merck KGaA, Darmstadt, Germany’s disease expertise in oncology and immunology, clinical development capabilities, and global footprint.

In January 2022, we entered into a strategic research collaboration with Sanofi to develop an AI-driven pipeline of precision-engineered, small molecule medicines. Through this collaboration, we are using our end-to-end integrated platform to discover and advance up to 15 novel targets in the oncology and immunology therapeutic areas. As part of this agreement, we received an upfront cash payment of $100 million, with the potential to receive up to $5.2 billion in total aggregate milestone payments plus tiered royalties.

In September 2021, we expanded our relationship with the Gates Foundation to develop small molecule therapeutics to help prepare for future pandemics. Building on smaller collaborations in the anti-infective and non-hormonal contraceptive space, we are focusing on programs targeting influenza, coronaviruses, and paramyxoviruses (e.g., Nipah). As part of this collaboration, the Gates Foundation made a $35 million equity investment into Exscientia.

The Bill & Melinda Gates Foundation is a funder of anti-infective programs

In 2019, we entered into a co-development and co-ownership joint venture with Rallybio to investigate treatments for patients with rare diseases. Following an assessment by our AI platform for biological pathway relevance and chemical druggability risks, the joint venture selected a target, ENPP1. Targeting ENPP1 offers a differentiated approach to current standard of care options for patients with hypophosphatasia (HPP). HPP is a rare, potentially life-threatening genetic disease, characterized by impaired mineralization of bones and teeth. Rallybio’s vital therapeutic area and clinical knowledge allows us to enter this therapeutic area of high unmet need.

In 2023, we entered into a strategic partnership with NVIDIA, backed by a $50 million investment, aimed at advancing our AI-enabled drug discovery mission. With NVIDIA's computing expertise and our vast proprietary biological and chemical dataset, the partnership is focused on scaling our foundation models in biology and chemistry and providing access to our public models through the NVIDIA BioNeMo platform.

In November 2023, we entered into a collaboration with Tempus to gain preferred access to one of the world’s largest proprietary, de-identified, patient-centric oncology datasets, spanning DNA, RNA, health records and more to support the discovery of potential biomarker-enriched therapeutics at scale through the training of causal AI models. By combining the forward genetics approach of Tempus with the reverse genetics approach at Recursion, we believe we have an opportunity to improve the speed, precision and scale of therapeutic development in oncology.

In May 2024, Recursion entered into a multi-year agreement with Helix to access hundreds of thousands of de-identified records including Helix’s Exome+® genomic data and data from longitudinal health records. Recursion plans to use this data to train causal AI models and design biomarker and patient stratification strategies across broad disease areas. The Helix dataset expands Recursion's integration of real-world patient data and complements Recursion's access to Tempus' oncology data.

In December 2023, we entered into a collaboration with Enamine to generate and design enriched compound libraries for the global drug discovery industry. By leveraging Recursion’s MatchMaker tool to identify compounds in the Enamine REAL Space predicted to bind to high-value targets, the companies believe they can generate more powerful compound libraries for drug discovery purposes. Enamine may offer the resulting libraries to customers for purchase and will co-brand any libraries under both the Enamine and MatchMaker trademarks.

In 2024, we expanded our collaboration with Google Cloud to leverage generative AI capabilities and advanced computing resources to advance our mission. This strategic partnership includes generative AI capabilities, including Gemini models, to support the RecursionOS, drive improved search and access with BigQuery, and help scale compute resources. In addition, Recursion has also made our OpenPhenom Foundation model available on Google Cloud. The enriched partnership supports Recursion's ongoing effort to tackle the biopharmaceutical industry's critical challenge of slow and costly drug development by reducing the time and cost involved in bringing new therapies to patients—ushering in a new era of accessible and affordable healthcare globally.